Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury

Érika B. Rangel, Samirah A. Gomes, Rosemeire Kanashiro-Takeuchi, Joshua M. Hare

Research output: Contribution to journalArticle

Abstract

Progenitor/stem cell-based kidney regenerative strategies are a key step towards the development of novel therapeutic regimens for kidney disease treatment. However, the route of cell delivery, e.g., intravenous, intra-arterial, or intra-parenchymal, may affect the efficiency for kidney repair in different models of acute and chronic injury. Here, we describe a protocol of intra-aorta progenitor/stem cell injection in rats following either acute ischemia-reperfusion injury or acute proteinuria induced by puromycin aminonucleoside (PAN) – the experimental prototype of human minimal change disease and early stages of focal and segmental glomerulosclerosis. Vascular clips were applied across both renal pedicles for 35 min, or a single dose of PAN was injected via intra-peritoneal route, respectively. Subsequently, 2 x 106 stem cells [green fluorescent protein (GFP)-labeled c-Kit+ progenitor/stem cells or GFP-mesenchymal stem cells] or saline were injected into the suprarenal aorta, above the renal arteries, after application of a vascular clip to the abdominal aorta below the renal arteries. This approach contributed to engraftment rates of ∼10% at day 8 post ischemia-reperfusion injury, when c-Kit+ progenitor/stem cells were injected, which accelerated kidney recovery. Similar rates of engraftment were found after PAN-induced podocyte damage at day 21. With practice and gentle surgical technique, 100% of the rats could be injected successfully, and, in the week following injection, ∼ 85% of the injected rats will recover completely. Given the similarities in mammals, much of the data obtained from intra-arterial delivery of progenitor/stem cells in rodents can be tested in translational research and clinical trials with endovascular catheters in humans.

Original languageEnglish (US)
Pages (from-to)1390-1403
Number of pages14
JournalCell Transplantation
Volume28
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Stem cells
Acute Kidney Injury
Aorta
Stem Cells
Puromycin Aminonucleoside
Rats
Kidney
Renal Artery
Proteins
Green Fluorescent Proteins
Reperfusion Injury
Surgical Instruments
Mammals
Catheters
Blood Vessels
Lipoid Nephrosis
Focal Segmental Glomerulosclerosis
Podocytes
Repair
Injections

Keywords

  • acute kidney injury
  • acute proteinuria
  • engraftment
  • ischemia-reperfusion injury
  • progenitor/stem cells
  • surgical technique

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury. / Rangel, Érika B.; Gomes, Samirah A.; Kanashiro-Takeuchi, Rosemeire; Hare, Joshua M.

In: Cell Transplantation, Vol. 28, No. 11, 01.11.2019, p. 1390-1403.

Research output: Contribution to journalArticle

@article{adaf387c6aab4f09aafd5d3b5511ce34,
title = "Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury",
abstract = "Progenitor/stem cell-based kidney regenerative strategies are a key step towards the development of novel therapeutic regimens for kidney disease treatment. However, the route of cell delivery, e.g., intravenous, intra-arterial, or intra-parenchymal, may affect the efficiency for kidney repair in different models of acute and chronic injury. Here, we describe a protocol of intra-aorta progenitor/stem cell injection in rats following either acute ischemia-reperfusion injury or acute proteinuria induced by puromycin aminonucleoside (PAN) – the experimental prototype of human minimal change disease and early stages of focal and segmental glomerulosclerosis. Vascular clips were applied across both renal pedicles for 35 min, or a single dose of PAN was injected via intra-peritoneal route, respectively. Subsequently, 2 x 106 stem cells [green fluorescent protein (GFP)-labeled c-Kit+ progenitor/stem cells or GFP-mesenchymal stem cells] or saline were injected into the suprarenal aorta, above the renal arteries, after application of a vascular clip to the abdominal aorta below the renal arteries. This approach contributed to engraftment rates of ∼10{\%} at day 8 post ischemia-reperfusion injury, when c-Kit+ progenitor/stem cells were injected, which accelerated kidney recovery. Similar rates of engraftment were found after PAN-induced podocyte damage at day 21. With practice and gentle surgical technique, 100{\%} of the rats could be injected successfully, and, in the week following injection, ∼ 85{\%} of the injected rats will recover completely. Given the similarities in mammals, much of the data obtained from intra-arterial delivery of progenitor/stem cells in rodents can be tested in translational research and clinical trials with endovascular catheters in humans.",
keywords = "acute kidney injury, acute proteinuria, engraftment, ischemia-reperfusion injury, progenitor/stem cells, surgical technique",
author = "Rangel, {{\'E}rika B.} and Gomes, {Samirah A.} and Rosemeire Kanashiro-Takeuchi and Hare, {Joshua M.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1177/0963689719860826",
language = "English (US)",
volume = "28",
pages = "1390--1403",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "11",

}

TY - JOUR

T1 - Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury

AU - Rangel, Érika B.

AU - Gomes, Samirah A.

AU - Kanashiro-Takeuchi, Rosemeire

AU - Hare, Joshua M.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Progenitor/stem cell-based kidney regenerative strategies are a key step towards the development of novel therapeutic regimens for kidney disease treatment. However, the route of cell delivery, e.g., intravenous, intra-arterial, or intra-parenchymal, may affect the efficiency for kidney repair in different models of acute and chronic injury. Here, we describe a protocol of intra-aorta progenitor/stem cell injection in rats following either acute ischemia-reperfusion injury or acute proteinuria induced by puromycin aminonucleoside (PAN) – the experimental prototype of human minimal change disease and early stages of focal and segmental glomerulosclerosis. Vascular clips were applied across both renal pedicles for 35 min, or a single dose of PAN was injected via intra-peritoneal route, respectively. Subsequently, 2 x 106 stem cells [green fluorescent protein (GFP)-labeled c-Kit+ progenitor/stem cells or GFP-mesenchymal stem cells] or saline were injected into the suprarenal aorta, above the renal arteries, after application of a vascular clip to the abdominal aorta below the renal arteries. This approach contributed to engraftment rates of ∼10% at day 8 post ischemia-reperfusion injury, when c-Kit+ progenitor/stem cells were injected, which accelerated kidney recovery. Similar rates of engraftment were found after PAN-induced podocyte damage at day 21. With practice and gentle surgical technique, 100% of the rats could be injected successfully, and, in the week following injection, ∼ 85% of the injected rats will recover completely. Given the similarities in mammals, much of the data obtained from intra-arterial delivery of progenitor/stem cells in rodents can be tested in translational research and clinical trials with endovascular catheters in humans.

AB - Progenitor/stem cell-based kidney regenerative strategies are a key step towards the development of novel therapeutic regimens for kidney disease treatment. However, the route of cell delivery, e.g., intravenous, intra-arterial, or intra-parenchymal, may affect the efficiency for kidney repair in different models of acute and chronic injury. Here, we describe a protocol of intra-aorta progenitor/stem cell injection in rats following either acute ischemia-reperfusion injury or acute proteinuria induced by puromycin aminonucleoside (PAN) – the experimental prototype of human minimal change disease and early stages of focal and segmental glomerulosclerosis. Vascular clips were applied across both renal pedicles for 35 min, or a single dose of PAN was injected via intra-peritoneal route, respectively. Subsequently, 2 x 106 stem cells [green fluorescent protein (GFP)-labeled c-Kit+ progenitor/stem cells or GFP-mesenchymal stem cells] or saline were injected into the suprarenal aorta, above the renal arteries, after application of a vascular clip to the abdominal aorta below the renal arteries. This approach contributed to engraftment rates of ∼10% at day 8 post ischemia-reperfusion injury, when c-Kit+ progenitor/stem cells were injected, which accelerated kidney recovery. Similar rates of engraftment were found after PAN-induced podocyte damage at day 21. With practice and gentle surgical technique, 100% of the rats could be injected successfully, and, in the week following injection, ∼ 85% of the injected rats will recover completely. Given the similarities in mammals, much of the data obtained from intra-arterial delivery of progenitor/stem cells in rodents can be tested in translational research and clinical trials with endovascular catheters in humans.

KW - acute kidney injury

KW - acute proteinuria

KW - engraftment

KW - ischemia-reperfusion injury

KW - progenitor/stem cells

KW - surgical technique

UR - http://www.scopus.com/inward/record.url?scp=85073578507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073578507&partnerID=8YFLogxK

U2 - 10.1177/0963689719860826

DO - 10.1177/0963689719860826

M3 - Article

C2 - 31409111

AN - SCOPUS:85073578507

VL - 28

SP - 1390

EP - 1403

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 11

ER -